COVID-19 FAQs

Is there any interruption to the supply of medicines based on COVID-19?  
- Amgen continues to provide an uninterrupted supply of medicines for patients, and based on inventory levels, we do not currently anticipate a shortage of our medicines due to COVID-19 at this time.

Where do I go to report an adverse event or contact a medical information professional?  
- For product questions, to report an adverse event or safety-related issue, or to report a quality issue with a product or device, call +1 800-772-6436 (800-77-AMGEN) or +1 805-447-3505. Local contact information by country can be found here.
- U.S. healthcare professionals can also visit www.amgenmedinfo.com

How can I receive support from the Otezla sales team?  
- Our sales team will be available remotely to support HCP office needs.
- Please contact your sales representative for Otezla samples and other Otezla resources you may need.

Will my patients still have access to Otezla SupportPlus™ (OSP)?  
- OSP will continue to provide services without interruption to ensure continuity of care of Otezla patients. OSP has enacted a plan to have the majority of the staff work remotely.
- OSP will work with HCP offices on a case by case basis to ensure patients do not lapse due to the COVID-19 pandemic.
- Field Reimbursement Managers will be available remotely and will continue to provide timely service to assist patients.
- Copay access and Bridge Program will continue without interruption.
- New and active Bridge patients will receive an additional Bridge pack to ensure minimal disruption as we seek prior authorization approvals.

What is the process to prescribe Otezla via telemedicine?  
- Complete the Otezla Start Form. Otezla Start Form is available on OtezlaPro.com https://www.otezlapro.com/resources/resource-center/
- Fax to OSP at: 1-855-850-2955
- A guide and helpful tips to prevent delays in completing the Otezla Start Form is available on OtezlaPro.com https://www.otezlapro.com/resources/resource-center/